Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CetuGEX (tomuzotuximab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Glycotope

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

TA-MUC1 elevation + EGFR expression	Colorectal Cancer	TA-MUC1 elevation + EGFR expression	Colorectal Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Breast Cancer	TA-MUC1 elevation + EGFR expression	Breast Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	TA-MUC1 elevation + EGFR expression	Head and Neck Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3
TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	TA-MUC1 elevation + EGFR expression	Non Small Cell Lung Cancer	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3	gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials gatipotuzumab + tomuzotuximab Sensitive : C3